80 related articles for article (PubMed ID: 2393858)
1. Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.
LoRusso PM; Aukerman SL; Polin L; Redman BG; Valdivieso M; Biernat L; Corbett TH
Cancer Res; 1990 Sep; 50(18):5876-82. PubMed ID: 2393858
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
Winkelhake JL; Stampfl S; Zimmerman RJ
Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
[TBL] [Abstract][Full Text] [Related]
3. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
4. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
6. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
7. Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
Nakamura S; Kashimoto S; Kajikawa F; Nakata K
Cancer Res; 1991 Jan; 51(1):215-21. PubMed ID: 1899039
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
Cabanes A; Even-Chen S; Zimberoff J; Barenholz Y; Kedar E; Gabizon A
Clin Cancer Res; 1999 Mar; 5(3):687-93. PubMed ID: 10100723
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy of murine mammary adenocarcinomas.
Ames IH
Anticancer Res; 2004; 24(4):2249-56. PubMed ID: 15330169
[TBL] [Abstract][Full Text] [Related]
10. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
11. Application of an interleukin 2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases.
Fujiwara T; Sakagami K; Matsuoka J; Shiozaki S; Uchida S; Fujioka K; Takada Y; Onoda T; Orita K
Cancer Res; 1990 Nov; 50(21):7003-7. PubMed ID: 2208166
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.
Nakamura S; Nakata K; Kashimoto S; Yoshida H; Yamada M
Jpn J Cancer Res; 1986 Aug; 77(8):767-73. PubMed ID: 3093425
[TBL] [Abstract][Full Text] [Related]
14. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activity.
Ades EW; McKemie CR; Wright S; Peacocke N; Pantazis C; Lockhart WL
Nat Immun Cell Growth Regul; 1987; 6(5):260-8. PubMed ID: 3502171
[TBL] [Abstract][Full Text] [Related]
16. Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy.
Corbett TH; Griswold DP; Roberts BJ; Peckham JC; Schabel FM
Cancer Treat Rep; 1978 Oct; 62(10):1471-88. PubMed ID: 709550
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor effect of combination therapy with interleukin-2 and polyribonucleotides against adenocarcinoma 755.
Iigo M; Nakajima Y; Nishikata K; Hoshi A
J Biol Response Mod; 1989 Apr; 8(2):147-54. PubMed ID: 2786554
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines.
Rodolfo M; Zilocchi C; Melani C; Cappetti B; Arioli I; Parmiani G; Colombo MP
J Immunol; 1996 Dec; 157(12):5536-42. PubMed ID: 8955204
[TBL] [Abstract][Full Text] [Related]
20. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
Kikuchi T; Miyazawa N; Moore MA; Crystal RG
Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]